Novo Nordisk A/S (NVO) is expected to report earnings on Wednesday, November 4, 2026, after the close. Consensus EPS estimate is $0.80.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $0.77 | $0.96 | +24.7% | $12.13B |
| 2026-05-06 | FY2026 Q1 | $0.87 | $1.04 | +19.5% | $11.02B |
| 2024-09-30 | FY2024 Q3 | $0.87 | $0.88 | +1.4% | $10.68B |
| 2024-06-30 | FY2024 Q2 | $0.70 | $0.66 | -5.9% | $9.80B |
| 2024-03-31 | FY2024 Q1 | $0.74 | $0.82 | +10.5% | $9.38B |
| 2023-12-31 | FY2023 Q4 | $0.66 | $0.71 | +7.6% | $9.60B |
| 2023-09-30 | FY2023 Q3 | $0.69 | $0.73 | +5.8% | $8.35B |
| 2023-06-30 | FY2023 Q2 | $0.67 | $0.63 | -6.0% | $8.03B |
NVO has beaten consensus EPS in 6 of its last 8 reported quarters.
See NVO on the live calendar →